CoChat

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Open access
Sebastian, Martin, Eberhardt, Wilfried E.E., Hoffknecht, Petra, Metzenmacher, Martin, Wehler, Thomas, Kokowski, Konrad, Alt, Jürgen, Schütte, Wolfgang, Büttner, Reinhard, Heukamp, Lukas C., Stenzinger, Albrecht, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Dille, Stephanie, Hipper, Annette, Sandberg, Marlen, Weichert, Wilko, Groschek, Matthias, von der Heyde, Eyck, Rauh, Jacqueline, Dechow, Tobias, Thomas, Michael, Griesinger, Frank · 2021 · Lung Cancer
Cited by 81

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: After decades of unsuccessful efforts in inhibiting KRAS, promising clinical data targeting the mutation subtype G12C emerge. Since little is known about outcome with standard treatment of patients with G12C mutated non-small cell lung cancer (NSCLC), we analyzed a large, representative, real-world cohort from Germany. PATIENTS AND METHODS: A total of 1039 patients with advanced KRAS-mutant or -wildtype NSCLC without druggable alterations have been recruited in the prospective, observational registry CRISP from 12/2015 to 06/2019 by 98 centers in Germany. Details on treatment, best response, and outcome were analyzed for patients with KRAS wildtype, G12C, and non-G12C mutations. RESULTS: Within the study population, 160 (15.4 %) patients presented with KRAS G12C, 251 (24.2 %) with non-G12C mutations, 628 (60.4 %) with KRAS wildtype. High PD-L1 expression (Tumor Proportion Score, TPS > 50 %) was documented for 28.0 %, 43.5 %, and 28.9 % (wildtype, G12C, non-G12C) of the tested patients; 68.8 %, 89.3 %, and 87.7 % of the patients received first-line treatment combined with an immune checkpoint-inhibitor in 2019. TPS > 50 % vs. TPS < 1 % was associated with a significantly decreased risk of mortality in a multivariate Cox model (HR 0.39, 95 % CI 0.26-0.60, p=<0.001). There were no differences in clinical outcome between KRAS wildtype, G12C or non-G12C mutations and KRAS mutational status was not prognostic in the model. CONCLUSION: Here we describe the so far largest prospectively recruited cohort of patients with advanced NSCLC and KRAS mutations, with special focus on the G12C mutation. These data constitute an extremely valuable historical control for upcoming clinical studies that employ KRAS inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2021.02.005

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 81

Metadata

Authors
Sebastian, M., Eberhardt, W. E. E., Hoffknecht, P., Metzenmacher, M., Wehler, T., Kokowski, K., Alt, J., Schütte, W., Büttner, R., Heukamp, L. C., Stenzinger, A., Jänicke, M., Fleitz, A., Zacharias, S., Dille, S., Hipper, A., Sandberg, M., Weichert, W., Groschek, M., von der Heyde, E., Rauh, J., Dechow, T., Thomas, M., & Griesinger, F.
Venue
Lung Cancer
Publisher
Elsevier BV
Published
2021-04
Volume
154
Pages
51-61
ISSN
0169-5002 (ISSN-L)
OpenAlex
W3129670908
Cited by
81
References
11
FWCI
8.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). https://app.cochat.ai/papers/10.1016/j.lungcan.2021.02.005
The paper
Sebastian, M., Eberhardt, W. E. E., Hoffknecht, P., Metzenmacher, M., Wehler, T., Kokowski, K., Alt, J., Schütte, W., Büttner, R., Heukamp, L. C., Stenzinger, A., Jänicke, M., Fleitz, A., Zacharias, S., Dille, S., Hipper, A., Sandberg, M., Weichert, W., Groschek, M., . . . Griesinger, F. (2021). KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. https://doi.org/10.1016/j.lungcan.2021.02.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.